Publication
Hypofractionated and stereotactic body proton radiotherapy for a high-risk lung cancer cohort: A multi-institutional experience from the proton collaborative group prospective registry.
Alexander J Allen, Charles B Simone, Kai Sun, David F Alicia, Ajay Banskota, Gopal K Bajaj, John H Chang, James R Gray, Ryan S Grover, Christian C Hyde, Jenna B Jatczak, Kara E Lehman, Mark W McDonald, Stephen A Mihalcik, Sina Mossahebi, Michelle R Mundis Myers, Yosan G Okbamichael, Stephanie M Perkins, Robert H Press, Zaker H Rana, Lane R Rosen, Ronny L Rotondo, Christopher C Sinesi, Henry K Tsai, James J Urbanic, Carlos E Vargas, Nathan Y Yu, Jing Zeng, Matthew J Ferris
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
INTRODUCTION: Lung cancer is commonly treated with stereotactic body radiotherapy (SBRT) and hypofractionated RT (HFRT). Delivering these ablative regimens with proton beam therapy (PBT) may yield dosimetric and clinical advantages, particularly for high-risk cases. We evaluated safety and efficacy…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Lung Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available